Stroke induces a multiphasic systemic immune response, but the consequences of this response on atherosclerosis-a major source of recurrent vascular events-have not been thoroughly investigated. We show that stroke exacerbates atheroprogression via alarmin-mediated propagation of vascular inflammation. The prototypic brain-released alarmin high-mobility group box 1 protein induced monocyte and endothelial activation via the receptor for advanced glycation end products (RAGE)-signaling cascade and increased plaque load and vulnerability. Recruitment of activated monocytes via the CC-chemokine ligand 2-CC-chemokine receptor type 2 pathway was critical in stroke-induced vascular inflammation. Neutralization of circulating alarmins or knockdown of RAGE attenuated atheroprogression. Blockage of 3-adrenoreceptors attenuated the egress of myeloid monocytes after stroke, whereas neutralization of circulating alarmins was required to reduce systemic monocyte activation and aortic invasion. Our findings identify a synergistic effect of the sympathetic stress response and alarmin-driven inflammation via RAGE as a critical mechanism of exacerbated atheroprogression after stroke.
INTRODUCTION
The risk of recurrent vascular events after stroke is high and remains elevated even years after first stroke (1, 2) . The enhanced risk of secondary events encompasses large artery stroke and myocardial infarction, both manifestations of atherosclerosis (3, 4) . Atherosclerosis is a chronic inflammatory condition of the arterial vessel wall, characterized by an imbalance in lipid metabolism and recruitment of immune cells leading to a chronic inflammatory milieu (5, 6) . Key steps further include infiltration by monocytes, secretion of proteolytic enzymes, fibrous cap thinning, and plaque rupture, eventually causing end-organ damage due to ischemia. Previous work in experimental myocardial infarction has demonstrated an accelerating effect of this event on atheroprogression (7, 8) , which has recently been linked to a stress-mediated mobilization of monocytes from bone marrow niches via adrenergic signaling (7) . The same study further provided initial evidence for accelerated atheroprogression after experimental stroke (7) . However, the mechanisms underlying enhanced atheroprogression after stroke have so far not been investigated.
Stroke promotes a multiphasic immunomodulation in the systemic immune compartment with an early sterile inflammatory response within hours and a chronic inflammatory response that is observed both in mice and in stroke patients (9) (10) (11) . We previously demonstrated that this systemic immunomodulation is triggered by alarmins released from necrotic brain tissue (12) . This specifically involves the prototypic alarmin high-mobility group box 1 (HMGB1). Alarmins can have chemoattractant as well as cytokine-inducing properties and interact with pattern recognition receptors such as toll-like receptors and the receptor for advanced glycation end products (RAGE) on various immune and nonimmune cell populations (13) .
In light of these observations, we hypothesized that stroke might promote vascular inflammation and atheroprogression via an alarmindriven systemic immune response. Here, we confirm exacerbation of atheroprogression after stroke and specifically identify a key role of the alarmin-RAGE pathway acting in synergy with the sympathetic stress response for de novo recruitment of activated monocytes to atherosclerotic lesions.
RESULTS

Stroke exacerbates atheroprogression via increased vascular monocyte recruitment
To determine the effect of stroke on exacerbation of atheroprogression, we fed 8-week-old apolipoprotein E-deficient (ApoE −/− ) mice (14) , a well-established mouse model for atherosclerosis, a high-cholesterol diet (HCD) for 8 weeks before the induction of experimental stroke and assessed plaque load after an additional 4 weeks of HCD (Fig. 1A  and fig. S1 ). Overall plaque load in whole aorta was significantly (P = 0.002) increased in mice undergoing stroke surgery compared to sham surgery as assessed by en face staining (Fig. 1B) . Likewise, significantly (P < 0.0001) increased plaque load was observed throughout the aortic valve ( Fig. 1 , C to E). Similar results were also obtained in female animals ( fig. S2 ). To evaluate whether stroke-induced plaque formation was accompanied by vascular inflammation, we next performed flow cytometric analysis of whole-aorta cell suspensions. In contrast to other immune cell populations ( fig. S3 ), monocyte cell counts and, more specifically, the number of proinflammatory CD11b + Ly6C high monocytes per aorta were increased after stroke compared to sham (Fig. 1, F and G) . We further found an increase in the enzymatic activity of matrix metalloproteinase 2 (MMP2) and MMP9 as detected by in situ zymography (Fig. 1, H and I ). Because increased MMP activity is associated with plaque instability (15) , we further investigated morphological markers of vulnerable plaques using previously established protocols (16) . Cap thickness was reduced, and the number of highly unstable plaques increased in mice undergoing stroke surgery compared to sham surgery, suggesting a more vulnerable plaque morphology after stroke (Fig. 1J) . Moreover, we analyzed plaques at the carotid bifurcation area, a predilected site for stenosis and plaque rupture in stroke patients, observing also in this area a trend toward increased plaque load after stroke ( fig. S4 ). To determine whether the increased vascular inflammation was due to local proliferation or de novo recruitment of proinflammatory monocytes, we next implanted osmotic pumps releasing bromdeoxyurdine (BrdU) for detection of cell proliferation. In addition, we intraperitoneally (ip) administered 1 × 10 7 CCR2 RFP/+ reporter monocytes, expressing red fluorescent protein (RFP) under the CC-chemokine receptor type 2 (CCR2) promoter, for detection of proinflammatory monocyte recruitment in HCD-fed ApoE −/− mice after stroke or sham surgery ( Fig. 2A) . Although we found no difference in the proliferation rate of aortic monocytes/macrophages as assessed by BrdU incorporation (Fig. 2B  and fig. S5 ), the recruitment of ip injected proinflammatory CCR2 RFP/+ reporter cells into the aorta was substantially increased in stroke compared to sham group (Fig. 2,  C and D, and fig. S6 ).
Stroke induces chemoattractant expression and endothelial activation
Next, we investigated the mechanisms underlying active aortic monocyte recruitment after stroke and explored the possibility that stroke treatment may elicit a specific chemokine/cytokine profile in the atherogenic aorta. To investigate the aortic chemokine profile, we performed a polymerase chain reaction (PCR) array for 86 chemokines and chemoattractant receptors using lysates of whole aortas obtained 3 days after stroke or sham surgery (table S1). We found that the transcription of 12 chemokines and chemoattractant receptors was up-regulated after stroke compared to sham (Fig. 2E) . Notably, the most up-regulated chemokine was CC-chemokine ligand 2 (CCL2), with a more than sixfold increase after stroke induction (fold change, 6.316; P = 0.018). CCL2 is secreted by foam cells in arterial lesions (17) and by activated endothelium (18) and attracts proinflammatory CCR2-expressing cells (19) (20) (21) . Hence, we analyzed serum of mice after stroke and found increased CCL2 concentrations compared to sham-operated mice 1 week after sham surgery (Fig. 2F ). In addition, we measured monocytic CCR2 expression by flow cytometry in aortas after stroke versus sham surgery, and we observed an increase in CCR2 + cell counts as well as CCR2 surface expression on inflammatory monocytes (Fig. 2G) . One week after stroke induction, we detected fewer CD11b +
Ly6C
high RFP + monocytes in the aortas of mice injected ip with homozygous CCR2 RFP/RFP (CCR2-deficient) compared to heterozygous CCR2 RFP/+ (CCR2-expressing) cells after stroke induction (Fig. 2H) , indicating a critical role of the CCL2-CCR2 pathway in attraction of proinflammatory monocytes to the aorta after stroke.
Atherogenic monocyte recruitment is mediated by an orchestrated interplay of chemokine/chemokine receptor and integrin/adhesion molecule interactions with a pivotal role for endothelial activation. We found an increase mRNA expression of Icam1 and Vcam1, key adhesion molecules in atherogenic monocyte recruitment, in aortas 3 days after stroke (Fig. 3A) . In vivo molecular magnetic resonance imaging (MRI) using microsized particles of iron oxide-labeled vascular cell adhesion molecule-1 (VCAM-1)-specific antibodies (22) revealed an increase in VCAM-1 signal volume at 5 days after stroke in aortic valves compared to baseline values before stroke induction (Fig. 3 , B to D). These experiments provided strong support for the activation of the aortic endothelium after stroke. We hypothesized that the observed endothelial activation was likely mediated by soluble, proinflammatory mediators released from the ischemic brain as previously described by our group (12) . To test this hypothesis, we used an in vitro endothelial culture system, subjecting murine aortic endothelial cells (MAECs) to stroke-or sham-conditioned plasma; control conditions included normal fetal calf serum-supplemented media with or without tumor necrosis factor- (TNF-) stimulation (Fig. 3E) . We found that mRNA expression of Vcam1, Icam1, and Il6 increased after conditioning with stroke plasma compared to sham plasma, with expression similar to stimulation of MAECs by TNF- (Fig. 3F) . Moreover, we found that addition of the soluble form of RAGE (sRAGE; 10 ng/ml) decreased the expression of Vcam1, Icam1, and Il6 after stimulating the MAECs with stroke plasma. These results support the concept of poststroke endothelial activation by soluble plasma mediators such as cytokines and alarmins-druggable by decoy receptors such as sRAGE-with an ensuing active recruitment of monocytes via CCR2-dependent pathways.
Poststroke alarmin release induces immune activation via the RAGE signaling pathway
Acute stroke leads to massive release of proinflammatory alarmins such as the prototypic alarmin HMGB1 from hypoxia-stressed and necrotic tissue (12) . We confirmed the increase of plasma HMGB1 concentrations acutely (24 hours) after experimental stroke and expanded this observation to the chronic phase (30 days) when HMGB1 plasma levels were still more than threefold elevated after stroke compared to sham (Fig. 4A ). We next reduced systemic alarmins in vivo using sRAGE as a decoy receptor for circulating alarmins (23) . We treated mice 30 min before surgery and 4 hours after surgery with an intraperitoneal bolus (4 mg/kg) of sRAGE or vehicle and compared monocytic activation and cytokine expression in whole-spleen (F) RE of Icam1, Vcam1, and Il6 mRNA in MAECs after being incubated with stroke or sham plasma and treated with soluble form of receptor for advanced glycation end products (sRAGE) (10 ng/ml) or vehicle (H test, n = 6 to 8 per group). For control conditions, fetal calf serum (FCS)-supplemented media without cytokine stimulus or with recombinant tumor necrosis factor- (TNF-; 20 ng/ml) were used. *P < 0.05, **P < 0.01, ***P < 0.001.
lysates 3 days after stroke. Compared to sham-operated mice, mice undergoing stroke surgery showed an increase of major histocompatibility complex class II (MHCII) expression as a monocytic activation marker (Fig. 4B ) and elevated Il6 and Tnfa mRNA expression (Fig. 4C) . In contrast, sRAGE treatment abrogated the increase in MHCII expression and cytokine mRNA expression after stroke (Fig. 4 , B and C). To investigate the role of soluble plasma mediators in monocyte activation more specifically, we treated primary monocyte cultures with recombinant HMGB1 or conditioned medium with plasma from sham-operated or stroked mice. Analysis of the mRNA expression revealed a dose-dependent increase in Il6 and Tnfa expression after treatment with recombinant endotoxin-free HMGB1 as well as plasma from stroked animals, confirming a key role for soluble mediators such as HMGB1 in the activation of monocytes (Fig. 4D) . Accordingly, we also detected substantially increased serum HMGB1 concentrations in human stroke patients both in the acute (within first 48 hours) and subacute phase (72 hours and 7 days) ( Fig. 4E and table S2). Analysis of the different human HMGB1 reduction/oxidation (redox) forms by mass spectroscopy identified the functionally relevant cytokine-inducing disulfide HMGB1 isoform as the predominant modification after 3 days after stroke (Fig. 4E ). This finding is in accordance with our previous observations on HMGB1 redox modifications in experimental stroke in mice showing that disulfide HMGB1 is the key mediator resulting in activation and expansion of the systemic monocyte population after stroke (12, 24, 25) . The increase of proinflammatory HMGB1 was reflected in the pattern of transient leukocytosis during the time course after stroke (Fig. 4F) . Moreover, C-reactive protein blood levels and neutrophil counts were increased after stroke, reflecting the alarmin-driven sterile inflammatory response ( fig. S7 ). Accordingly, we also detected an increase in the frequency of activated human leukocyte antigen (HLA-DR + ) cells 2 months after human stroke (Fig. 4G) . ) cell count as an indication of monocyte activation at up to 60 days after large IS compared to age-matched controls (t test, n = 12 to 17 per group). *P < 0.05, **P < 0.01, ***P < 0.001.
In light of the effective abrogation of the poststroke systemic immune response in the presence of sRAGE, we aimed to test the effect of sRAGE treatment on stroke-induced atheroprogression. Atherosclerotic animals were treated before and after surgery with an intraperitoneal bolus (4 mg/kg) of sRAGE, and aortic plaque load was analyzed after sham or stroke surgery (Fig. 5A) . We found reduced plaque loads in aortas of mice receiving sRAGE compared to controltreated mice after stroke, whereas no difference was detected for the sham-operated groups between control and sRAGE treatment (Fig. 5B) . Correspondingly, the overall survival rate and normalization of poststroke weight loss were improved in sRAGE-treated animals ( fig. S8) , and the same pattern of treatment efficacy was observed for the plaque load in aortic valves ( fig. S9 ). In addition, flow cytometric analysis revealed that sRAGE abrogated poststroke increase in total CD45 + CD11b
+ as well as CD11b + Ly6C high proinflammatory mono cyte cell counts in aortas 4 weeks after stroke induction (Fig. 5C) . Assessment of the lipid profiles of HCD-fed ApoE −/− mice revealed no differences after stroke induction and sRAGE treatment, except for the nonatherogenic (26) triglyceride levels ( fig. S10) .
Given the potent effect of sRAGE on neutralizing the effects of poststroke alarmins on vascular inflammation and atheroprogression, we aimed to more specifically investigate the contribution of the RAGE-dependent pathway. To down-regulate RAGE in vivo, we administered RAGE-specific small interfering RNA (siRNA) in HCDfed ApoE −/− mice and found a knockdown of aortic RAGE mRNA and protein expression 3 days after hydrodynamic intravenous siRNA injection of 10 nmol of RAGE-silencing or negative control siRNA (Fig. 5, D and E) . siRNA-induced RAGE knockdown reduced aortic total and proinflammatory monocyte counts 7 days after stroke induction compared to control treatment with unspecific siRNA (Fig. 5F ). As RAGE also engages lig ands other than HMGB1, we next aimed to test the specific contribution of HMGB1 as a potential mediator leading to RAGE-mediated atheroprogression. Neutralizing circulating HMGB1 by intraperitoneal injection of HMGB1-specific monoclonal antibodies (4 mg/kg) immediately after experimental ischemia attenuated the increase in cellular vascular inflammation after stroke induction (Fig. 5G) . However, neither infarct volume nor behavioral deficits were affected by the sRAGE or HMGB1-specific antibody treatment compared to control treatment 1 week after experimental stroke. Moreover, using HMGB1-specific antibodies in wild-type (WT) mice reduced monocyte expansion and activation in blood and increased cell number in spleen 24 hours after stroke ( fig. S11 ). To further elaborate on the role of HMGB1 as a proinflammatory mediator of atheroprogression, we administered recombinant HMGB1 to HCD-fed ApoE −/− mice without any surgical intervention. We found increased monocyte counts in whole-aorta lysates (Fig. 5H ) and exacerbated plaque loads in aortic valves 7 days after HMGB1 injection (Fig. 5, I and J). In addition, we detected an up-regulation of Il6, Icam1, and Vcam1 mRNA expression in whole-aorta lysates ( fig. S12 ), resembling the proinflammatory expression pattern found in aortas of mice undergoing stroke (compared to Fig. 3A) . Together, these results indicate that HMGB1-and potentially other alarmins released from the necrotic brain tissueinduces a sterile, systemic immune response via vascular RAGE, which in turn results in exacerbation of vascular inflammation after stroke.
Alarmin release and sympathetic stress response synergize in poststroke atheroprogression
We aimed to further dissect the differential contribution of the sympathetic innervation versus alarmin-driven cascades on the observed effects of systemic immune activation and vascular inflammation after stroke. In accord with earlier findings (27), we observed a decrease in overall myeloid cell count of the femur bone marrow at 24 hours after stroke (Fig. 6A) . This was associated with an increase in tyrosine hydroxylase expression along sympathetic fibers in the femur bone marrow (Fig. 6, B and C) . These results indicated a potential release of monocytes from the bone marrow after sympathetic innervation due to a stroke-induced stress response. We and others previously observed a splenic expansion of myeloid cells after stroke induction (12, 28) . Hence, we tested the possibility of myeloid cell trafficking from the bone marrow to the spleen after stroke using an in vivo cell-tracking approach. After in vivo labeling of the bone marrow by quantum dot (Qdot) nanocrystals-nanometer-scaled fluorophores incorporated in the cytoplasm of living cells-we found an increased number of Qdot + monocytes in spleen after stroke compared to sham surgery (Fig. 6, D and E) , whereas the Qdot + cell count in bone marrow decreased after stroke ( fig. S13 ). To further investigate the contribution of the splenic immune compartment to poststroke vascular inflammation, we performed splenectomy versus sham surgery in HCDfed ApoE −/− mice before stroke induction in both groups. Seven days after stroke, we found reduced aortic monocyte counts in splenectomized animals and a decreased plaque load in aortic valves compared to the nonsplenectomized but stroked control group (Fig. 6 , F and G); however, splenectomy had no effect on infarct severity or bone marrow monocyte count ( fig. S14 ). Together, these findings suggest a role for sympathetic innervation in mobilization of myeloid cells from the bone marrow niche as well as maturation/activation of monocytes in the splenic immune compartment, thus contributing to strokeinduced atheroprogression.
To further test this hypothesis, we analyzed the differential contribution of the alarmin signaling cascade and sympathetic innervation on monocyte cellularity and activation using sRAGE decoy receptors and the 3-adrenoreceptor inhibitor SR59230A (7, 29) . Blocking 3-adrenoreceptors but not sRAGE treatment suppressed the egress of CD11b + CD45 + monocytes from the bone marrow, whereas both treatment regimens increased overall spleen cellularity (Fig. 6, H  and I) . Notably, 3-adrenoreceptor blockage did not alter HMGB1 plasma concentrations after stroke ( fig. S15 ). sRAGE treatment abrogated monocyte activation in the spleen after stroke, whereas adrenoreceptor blockage affected MHCII up-regulation only when applied in combination with sRAGE (Fig. 6J) . In blood, we observed similar treatment effects with only the combination of adrenoreceptor and sRAGE blockage being effective in decreasing monocyte activation ( fig. S16 ). We further investigated synergistic effects of neutralizing sympathetic activation and alarmin neutralization on exacerbation of vascular inflammation after stroke. Although both treatments attenuated the increase in aortic monocyte counts after stroke, blocking of alarmin signaling using sRAGE was required to attenuate the increase in activated MHCII + monocytes in atherosclerotic lesions after stroke (Fig. 6K) . We additionally analyzed the impact of adrenoreceptor and sRAGE blockage on aortic valve plaque load. In accordance with the synergistic effects of adrenoreceptor and sRAGE blockage on inflammatory markers of vascular inflammation, only the combined treatment was effective in reducing aortic plaque load compared to the control treatment (Fig. 6L) . These results suggest that sympathetic activation during the acute stress response after stroke drives bone marrow egress of monocytic cells, whereas brain-released alarmins are required for monocyte activation ( fig. S17 ).
of 11 DISCUSSION
Large-artery atherosclerosis is a major cause of stroke that is also associated with an unexpectedly high recurrence rate (1, 2) . We have shown that experimental stroke induces exacerbation of atheroprogression. Enhanced vascular inflammation after stroke depended on a synergistic effect of sympathetic recruitment of monocytes from the bone marrow niche and subsequent activation of innate immune and endothelial cells by circulating alarmins, attracting inflammatory monocytes to atherosclerotic lesions. We further identified the HMGB1-RAGE pathway as a critical signaling mechanism eliciting the sterile inflammatory response after stroke. We observed a rapid translocation of bone marrow monocytes to the spleen after stroke. Myeloid monocyte mobilization has previously been shown to be critically mediated by sympathetic signaling via 3-adrenoreceptors in myocardial infarction models (27) . Accordingly, we showed an important role of 3-adrenoreceptors in stroke-induced monocyte mobilization using specific inhibitors. However, although blocking sympathetic innervation attenuated monocyte evasion from the bone marrow, it did not affect monocyte activation, vascular inflammation, or plaque growth. Notably, previous studies in experimental and clinical stroke have associated the sympathetic stress response with subacute im munosuppression but not monocyte activation or vascular inflammation (30) . Hence, our results strengthen the concept of a second mechanism promoting the inflammatory response after stroke, independent of sympathetic activation.
Aside from eliciting a local immune response with microglial activation, the release of HMGB1 and other alarmins from necrotic brain tissue induces a systemic response with cellular activation and massive cytokine secretion in peripheral immune organs (10, 12) . Systemic immune activation involves a rapid sterile immune response acutely after stroke, followed by an immunosuppression during the subacute phase (days 2 to 7) after stroke. In addition, previous clinical studies have demonstrated a third phase characterized by a delayed chronic immune activation (from day 7 on) with elevated inflammatory markers for more than 1 year after stroke in patients (9, 31) . The biological activity of HMGB1 depends critically on its redox state (32, 33) . Fully reduced HMGB1 has chemoattractant properties, whereas disulfide HMGB1 has cytokine-inducing properties and the terminally oxidized sulfonyl HMGB1 is anti-inflammatory (11) . We observed that HMGB1 levels in stroke patients not only remained substantially increased during the first week after stroke but that the proinflammatory disulfide HMGB1 species became the predominant isoform over this time course. Monocytes/macrophages play a critical role in the development and propagation of atherosclerotic lesions. Monocyte invasion into atherogenic lesions has been shown to be instrumental in the initiation of atherosclerosis. In this phase, the chemokine-ligand receptor interaction plays a pivotal role. Studies have shown that CCR2 expression on monocytes is essential for recruitment into the adventitial space and for further plaque development (34, 35) . In contrast, proliferation of macrophages has been demonstrated to be the key driver for lesion growth in established atherosclerosis (36) . Surprisingly, we observed that poststroke exacerbation of established atherosclerotic lesions was associated with enhanced de novo recruitment of circulating monocytes to the vessel rather than increased local proliferation. A possible explanation for this phenomenon is that as a consequence of the strong inflammatory response after stroke, monocyte chemoattraction via the CCL2-CCR2 axis regains a predominant role for monocyte recruitment comparable to the initiation of the vascular inflammatory milieu (37) . Aside from chemoattraction, endothelial expression of adhesion molecules is pivotal for monocyte recruitment. Intercellular adhesion molecule-1 (ICAM-1) and VCAM-1 are known to be essential for the arrest and extravasation of monocytes into the arterial wall (38) . Our data unequivocally demonstrate the up-regulation of these critical adhesion molecules on aortic endothelial cells in mice by PCR, in vivo imaging, and in vitro cultures. In accord with our results, it was previously shown that HMGB1 can activate endothelial cells, leading to changes in the nuclear factors Sp-1 and nuclear factor B, with subsequent up-regulation of adhesion molecules and proinflammatory cytokines (18) .
We observed a highly consistent effect of poststroke exacerbation of atherosclerosis pathology both in female and male mice, in aortas and aortic valves, and verified this phenomenon by in vivo MRI. However, a limitation of this study is that we were not able to fully investigate the link between poststroke atheroprogression and enhanced plaque rupture as a cause of recurrent stroke in the mouse atherosclerosis model. Atherosclerotic lesions of aorta and large arteries in animal models, including the ApoE-deficient model used here, rarely develop spontaneous destabilization and rupture with occlusive vascular thrombosis. We observed several surrogate markers of increased plaque vulnerability; however, increased incidence of plaque rupture and secondary ischemic brain lesions will have to be tested in more specific models that mimic human plaque rupture and ultimately in prospective clinical studies.
In conclusion, our data identify stroke-induced alarmin release from the ischemic brain as a critical mechanism activating inflammatory pathways and acting in synergy with an acute stress response after stroke to exacerbate atherosclerosis. Interfering with this sterile immune response by neutralizing brain-released alarmins may provide a therapeutic approach for stroke patients.
MATERIAL AND METHODS
Study design
The goal of this study was to investigate atheroprogression after stroke and describe the underlying mechanisms in an experimental model of ischemic stroke in ApoE −/− mice. Sample sizes were calculated using GPower 3.1. On the basis of a previous report (7), we used a monocyte increase rate of 40% with an SD of 25%. Using an  error of 0.05 and power of 0.8, we calculated a group size of 8 (t test, two groups, unpaired).
Data were excluded from all mice that died during surgery. Detailed exclusion criteria for the experimental models were (i) insufficient middle cerebral artery (MCA) occlusion (blood flow reduction less than 80%), (ii) death during surgery, and (iii) lack of brain ischemia as quantified by histology (see table S3 for included/excluded animals per experiment). Animals were randomized to treatment groups, and all analy ses were performed by investigators blinded to group allocation. Unblinding was performed after completion of statistical analysis. All animal experiments were performed and reported in accordance with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (39) .
Experimental animals
All animal experiments were performed in accordance with the guidelines for the use of experimental animals and were approved by the government committee of Upper Bavaria (Regierungspraesidium Oberbayern, #175-2013). We used age-matched, male C57BL6/J mice (8 to 10 weeks, 22 to 24 g body weight; Charles River Laboratories). ApoE −/− (the Jackson Laboratory) mice were fed an HCD (#88137, ssniff). Transient filament occlusion was performed in all ApoE −/− after 8 weeks of HCD. CCR2-RFP knock-in mice were bred with CX3CR1-green fluorescent protein (GFP) mice (40) .
Clinical stroke patient study population
Ischemic stroke patients were recruited within 24 hours of symptom onset. All patients had a final diagnosis of ischemic stroke as defined by an acute focal neurological deficit in combination with a diffusionweighted imaging-positive lesion on MRI or a new lesion on a delayed computed tomography scan. Age-and comorbidity-matched patients without neurological disease were used as controls. The study was approved by the local ethics committee and was conducted in accordance with the Declaration of Helsinki and institutional guidelines. Written and informed consent was obtained from all subjects.
Statistical analysis
Data were analyzed using GraphPad Prism version 6.0. All summary data are expressed as means ± SD. All data sets were tested for normality using the Shapiro-Wilk normality test. The groups containing normally distributed data were tested using a two-way Student's t test (for two groups) or analysis of variance (ANOVA) (for more than two groups). The remaining data were analyzed using the MannWhitney U test (for two groups) or H test (for more than two groups). Similar variance was assured for all groups, which were statistically compared. Differences with a P < 0.05 were considered to be statistically significant. P values were adjusted for comparison of multiple comparisons using Bonferroni correction.
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